Combined kinase inhibition modulates parkin inactivation
Identifieur interne : 000897 ( Main/Exploration ); précédent : 000896; suivant : 000898Combined kinase inhibition modulates parkin inactivation
Auteurs : Elena Rubio De La Torre ; Berta Luzn-Toro ; Irene Forte-Lago ; Adolfo Minguez-Castellanos ; Isidro Ferrer ; Sabine Hilfiker [Espagne]Source :
- Human Molecular Genetics [ 0964-6906 ] ; 2009-03-01.
Abstract
Mutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunction may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise function remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphorylation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this post-translational modification for parkin function has remained unclear. Here we report that compound phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphorylation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent novel combinatorial therapeutic targets for treating PD.
Url:
DOI: 10.1093/hmg/ddn407
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Combined kinase inhibition modulates parkin inactivation</title><author><name sortKey="Rubio De La Torre, Elena" sort="Rubio De La Torre, Elena" uniqKey="Rubio De La Torre E" first="Elena" last="Rubio De La Torre">Elena Rubio De La Torre</name></author><author><name sortKey="Luzn Toro, Berta" sort="Luzn Toro, Berta" uniqKey="Luzn Toro B" first="Berta" last="Luzn-Toro">Berta Luzn-Toro</name></author><author><name sortKey="Forte Lago, Irene" sort="Forte Lago, Irene" uniqKey="Forte Lago I" first="Irene" last="Forte-Lago">Irene Forte-Lago</name></author><author><name sortKey="Minguez Castellanos, Adolfo" sort="Minguez Castellanos, Adolfo" uniqKey="Minguez Castellanos A" first="Adolfo" last="Minguez-Castellanos">Adolfo Minguez-Castellanos</name></author><author><name sortKey="Ferrer, Isidro" sort="Ferrer, Isidro" uniqKey="Ferrer I" first="Isidro" last="Ferrer">Isidro Ferrer</name></author><author><name sortKey="Hilfiker, Sabine" sort="Hilfiker, Sabine" uniqKey="Hilfiker S" first="Sabine" last="Hilfiker">Sabine Hilfiker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8EF30814B328D9B22835C471B32D3A63786CD43D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/hmg/ddn407</idno><idno type="url">https://api.istex.fr/document/8EF30814B328D9B22835C471B32D3A63786CD43D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D38</idno><idno type="wicri:Area/Main/Curation">000B81</idno><idno type="wicri:Area/Main/Exploration">000897</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Combined kinase inhibition modulates parkin inactivation</title><author><name sortKey="Rubio De La Torre, Elena" sort="Rubio De La Torre, Elena" uniqKey="Rubio De La Torre E" first="Elena" last="Rubio De La Torre">Elena Rubio De La Torre</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation></author><author><name sortKey="Luzn Toro, Berta" sort="Luzn Toro, Berta" uniqKey="Luzn Toro B" first="Berta" last="Luzn-Toro">Berta Luzn-Toro</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation></author><author><name sortKey="Forte Lago, Irene" sort="Forte Lago, Irene" uniqKey="Forte Lago I" first="Irene" last="Forte-Lago">Irene Forte-Lago</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation></author><author><name sortKey="Minguez Castellanos, Adolfo" sort="Minguez Castellanos, Adolfo" uniqKey="Minguez Castellanos A" first="Adolfo" last="Minguez-Castellanos">Adolfo Minguez-Castellanos</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation></author><author><name sortKey="Ferrer, Isidro" sort="Ferrer, Isidro" uniqKey="Ferrer I" first="Isidro" last="Ferrer">Isidro Ferrer</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation></author><author><name sortKey="Hilfiker, Sabine" sort="Hilfiker, Sabine" uniqKey="Hilfiker S" first="Sabine" last="Hilfiker">Sabine Hilfiker</name><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Espagne</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Human Molecular Genetics</title><idno type="ISSN">0964-6906</idno><idno type="eISSN">1460-2083</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-03-01">2009-03-01</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="809">809</biblScope><biblScope unit="page" to="823">823</biblScope></imprint><idno type="ISSN">0964-6906</idno></series><idno type="istex">8EF30814B328D9B22835C471B32D3A63786CD43D</idno><idno type="DOI">10.1093/hmg/ddn407</idno><idno type="ArticleID">ddn407</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0964-6906</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Mutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunction may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise function remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphorylation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this post-translational modification for parkin function has remained unclear. Here we report that compound phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphorylation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent novel combinatorial therapeutic targets for treating PD.</div></front></TEI><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Ferrer, Isidro" sort="Ferrer, Isidro" uniqKey="Ferrer I" first="Isidro" last="Ferrer">Isidro Ferrer</name><name sortKey="Forte Lago, Irene" sort="Forte Lago, Irene" uniqKey="Forte Lago I" first="Irene" last="Forte-Lago">Irene Forte-Lago</name><name sortKey="Luzn Toro, Berta" sort="Luzn Toro, Berta" uniqKey="Luzn Toro B" first="Berta" last="Luzn-Toro">Berta Luzn-Toro</name><name sortKey="Minguez Castellanos, Adolfo" sort="Minguez Castellanos, Adolfo" uniqKey="Minguez Castellanos A" first="Adolfo" last="Minguez-Castellanos">Adolfo Minguez-Castellanos</name><name sortKey="Rubio De La Torre, Elena" sort="Rubio De La Torre, Elena" uniqKey="Rubio De La Torre E" first="Elena" last="Rubio De La Torre">Elena Rubio De La Torre</name></noCountry><country name="Espagne"><noRegion><name sortKey="Hilfiker, Sabine" sort="Hilfiker, Sabine" uniqKey="Hilfiker S" first="Sabine" last="Hilfiker">Sabine Hilfiker</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000897 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000897 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8EF30814B328D9B22835C471B32D3A63786CD43D
|texte= Combined kinase inhibition modulates parkin inactivation
}}
| This area was generated with Dilib version V0.6.23. |  |